Drug utilization study of antihypertensive drugs in hypertensive diabetic patients in a tertiary care hospital

Shrinivas R. Raikar, Shivaraj B. Patil, Dayanand R. Raikar, Nagendra Mantale


Background: Diabetes along with hypertension is a very common ailment afflicting millions of people worldwide. The socio-economic stress caused by the morbidity and mortality associated with it is mind boggling. Hence, this study was undertaken to study the utilization of antihypertensive drugs in hypertensive diabetic patients.

Methods: A prospective study was conducted on 100 hypertensive diabetic patients aged between 18 and 90 years of either gender attending Basaveshwar Teaching and General Hospital, Kalaburagi. The data collected were statistically analyzed and presented as counts and percentages.

Results: In our study, we found that majority (63%) were male patients and majority belonged to 51-70 years age group. The majority of the patients were prescribed angiotensin converting enzyme inhibitors (ACEIs) alone (19%), followed by a combination of ACEIs and calcium channel blockers (9%). The generic prescribing was only 23%, and patient’s knowledge of correct dosage was 64%.

Conclusion: In this study, it has been observed that the antihypertensives drugs were prescribed rationally, but the generic prescribing was only 23% which is inappropriate prescribing behavior. Hence, physicians should be educated to prescribe drugs in the generic name so that the cost of drugs is reduced.


Angiotensin-converting enzyme inhibitors, Antihypertensive, Drug utilization, WHO core indicators

Full Text:



International Diabetes Federation. IDF Diabetes Atlas. 5th Edition. Brussels, Belgium: International Diabetes Federation; 2011.

Kotchen TA. Hypertensive vascular disease. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 18th Edition. New York: McGraw-Hill; 2012: 2842-91.

Shalini S, Ravichandran V, Mohanty BK, Dhanara SK, Saraswathi R. Drug utilization studies–an overview. Int J Pharm Sci Nanotechnol. 2010;3(1):803-10.

Tully MP, Ashcroft DM, Dornan T, Lewis PJ, Taylor D, Wass V. The causes of and factors associated with prescribing errors in hospital inpatients: a systematic review. Drug Saf. 2009;32(10):819-36.

Aronson JK. Medication errors: what they are, how they happen, and how to avoid them. QJM. 2009;102(8):513-21.

McDowell SE, Ferner HS, Ferner RE. The pathophysiology of medication errors: how and where they arise. Br J Clin Pharmacol. 2009;67(6):605-13.

John LJ, Devi P, John J, Arifulla M, Guido S. Utilization patterns of central nervous system drugs: a cross-sectional study among the critically ill patients. J Neurosci Rural Pract. 2011;2(2):119-23.

Keane WF, Anderson S, Aurell M, de Zeeuw D, Narins RG, Povar G, et al. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Ann Intern Med. 1989;111(6):503-16.

Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18(6):523-30.

Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709-16.

Uusitupa M, Siitonen O, Aro A, Pyörälä K. Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1985;28(1):22-7.

Isenalumhe AE, Oviawe O. Polypharmacy: its cost burden and barrier to medical care in a drug-oriented health care system. Int J Health Serv. 1988;18(2):335-42.

Veehof LJ, Stewart RE, Meyboom-de Jong B, Haaijer-Ruskamp FM. Adverse drug reactions and polypharmacy in the elderly in general practice. Eur J Clin Pharmacol. 1999;55(7):533-6.

Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38(6):666-71.

Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, CAPPP Study Group, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker–based treatment regimen a subanalysis of the captopril prevention project. Diabetes Care. 2001;24(12):2091-6.

Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-6.

Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534-44.